5 - Contents

6-7 NEWS
Roche to acquire Telavant for over $7.1bn; Pfizer’s meningococcal vaccine granted FDA approval

8-9 NEWS
‘Unworkable’ changes to UK medicines scheme; EU study reveals challenges of living with skin conditions

10-11 CORONAVIRUS NEWS
Nobel Prize awarded to pair behind mRNA vaccines; Novavax’s updated COVID-19 vaccine approved

12 DARWIN'S MEDICINE
How to put a firm’s malignancy into remission

13 POLICY AND PUBLIC HEALTH
Why Biden’s healthcare policy changes will be remembered for decades to come

14 INJECTING SOME HUMOUR
Do we have a tendency to be too serious in our healthcare marketing and comms?

15 INNOVATIVE IMPACT BLOG
Seven steps for cohesive strategic life cycle planning

16-17 CONNECTED DEVICES:
KEY CONSIDERATIONS FOR
PHARMACEUTICAL COMPANIES
The essential areas pharmaceutical companies should cover during decision-making and product development phases to get the most out of connected drug delivery devices

18-19 TURNING THE UK INTO AN MRNA SUPERPOWER: WHAT WOULD IT TAKE?
How the UK can harness the potential of mRNA technology to play a global leading role and be a driving force of the bio-industrial revolution

20-21 THE RISE OF DIGITAL
HEALTHCARE – FUELLED BY OPEN
INNOVATION IN HEALTHTECH HUBS
How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development

22-23 MILLENNIALS: THE WELLNESS GENERATION
Looking at the results from a global healthcare research study focusing on the patients of the future

26-27 FOCUSING IN ON REAL-WORLD EVIDENCE AND ITS CAPABILITIES
This month, Danny Buckland looks at the surge in real-world data and how it presents opportunities for greater understanding of patients and conditions, but still needs standardising and harmonising to liberate its full potential

30-32 PHARMA AI: HOW SALES AND MARKETING ARE STARTING TO STEP OUT OF R&D’S SHADOW
While it looks like there will be no shortage of AI progress for pharma and biotech R&D, the sector has had less experience with applying the technology within its commercial organisations. Now, with the rapid ascent of generative AI tools, this year is poised to be the turning point for commercial pharma organisations and artificial intelligence

37 HEALTHCARE COMMS
Eversana acquires Healthware Group;
Inizio Engage launches new learning and capability brand Nazaré

November 2023